REPORTING

Report Date:	OCT-04-2020
Receipt Date:	SEP-29-2020
Collection Date:	SEP-28-2020
Specimen:	Blood
Status:	FINAL

PHYSICIAN
John Miller

Account: Pleasantville Oncology
Address: 1234 Main Street
Anaheim, CA 94063, United States Ph: (123) 456-7890 | Fax: (123) 456-7899
Additional Recipient: N/A

Complete Tumor Response Map on page 3

This content is provided as a professional service and has not been reviewed or approved by the FDA

Summary of Detected Somatic Alterations, Immunotherapy Biomarkers & Associated Treatment Options

KEY ✓ Approved in indication ~ Approved in other indication ⊗ Lack of response

Detected Alteration(s) / Biomarker(s)	Associated FDA-approved therapies	Clinical trial availability (see page 5)	% cfDNA or Amplification
CDKN2A R80*	✓ Abemaciclib, Palbociclib, Ribociclib	Yes	11.9%
CDKN2A D74N	✓ Abemaciclib, Palbociclib, Ribociclib	Yes	0.8%
MSI-High	✓ Pembrolizumab ~ Atezolizumab, Avelumab, Durvalumab, Nivolumab	Yes	DETECTED
FGFR1 Amplification	~ Erdafitinib, Lenvatinib, Nintedanib, Pazopanib, Pemigatinib, Ponatinib	Yes	Medium (++)
PIK3CA Amplification	None	Yes	High (+++)

Variants of Uncertain Significance
ARID1A A1408T (12.9%), *CDKN2A* A68T (7.1%), *BRCA2* V831I (0.3%), *AR* A700S (0.2%)
The functional consequences and clinical significance of alterations are unknown. Relevance of therapies targeting these alterations is uncertain.

Synonymous Alterations
APC T1218T (17.7%), *NOTCH1* A2250A (2.6%), *ATM* N859N (0.2%), *MYC* S166S (0.2%)
This sequence change does not alter the amino acid at this position and is unlikely to be a therapeutic target. Clinical correlation is advised.

Additional Biomarkers

Biomarker	Additional Details
MSI-High	DETECTED

This content is provided as a professional service and has not been reviewed or approved by the FDA